Dopamine enhances somatostatin receptor-mediated inhibition of adenylate cyclase in rat striatum and hippocampus

Journal of Neuroscience Research

Volumn 48, Issue 3, 1997, Pages 238-248

  Rodriguez Sanchez M N ^a   Puebla, L ^a   Lopez Sanudo S ^a   Rodriguez Martin E ^a   Martin Espinosa A ^a   Rodriguez Pena M S ^a   Juarranz, M G ^a   Arilla, E ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

adenylyl cyclase; dopamine; G proteins; SCH 23390; somatostatin receptor; spiperone

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENYLATE CYCLASE; DOPAMINE; FORSKOLIN; SOMATOSTATIN RECEPTOR; SPIPERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ENZYME INHIBITION; HIPPOCAMPUS; INTERNEURON; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ADENYLATE CYCLASE; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; ENZYME INHIBITORS; FORSKOLIN; GTP-BINDING PROTEINS; HIPPOCAMPUS; IMMUNOLOGIC TECHNIQUES; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SPIPERONE;

EID: 0030892828     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19970501)48:3<238::AID-JNR6>3.0.CO;2-G     Document Type: Article

References (62)

1. Asanuma M, Ogawa N, Sora YH, Pongdhana K, Haba K, Mori A (1990): Alterations of somatostatin and its modulation by levodopa in MPTP-treated mouse brain. J Neurol Sci 100:155-160.
2. 2 receptor antagonists decrease prosomatostatin mRNA expression in rat striatum. Neuroscience 44:35-44.
3. Barinaga M, Bilezikjian LM, Vale W, Rosenfeld MG, Evans RM (1985): Independent effects of growth hormone releasing factor on growth hormone release and gene transcription. Nature 314:279-286.
4. Beal MF, Martin JB (1984): Effects of neuroleptic drugs on brain somatostatin-like immunoreactivity. Neurosci Lett 47:125-130.
5. Björklund A, Lindvall O (1984): Dopamine-containing systems in the CNS. In Björklund A, Hökfelt T (eds): "Handbook of Chemical Neurotransmitters." vol. 2. Amsterdam: Elsevier, pp 55-122.
6. Bokoch GM, Katada T, Northup JK, Hewlett EL, Gilman AG (1983): Identification of the predominant substrate for ADP-ribosylation by islet activating protein. J Biol Chem 258:2072-2075.
7. Chesselet MF, Reisine T (1983): Somatostatin regulates dopamine release in rat striatal slices and cat caudate nucleus. J Neurosci 3:232-236.
8. Chneiweiss J, Glowinski J, Prémont J (1985a): Vasoactive intestinal polypeptide receptors linked to an adenylate cyclase, and their relationship with biogenic amine- and somatostatin-sensitive adenylate cyclases on central neuronal and glial cells in primary cultures. J Neurochem 44:779-786.
9. Chneiweiss J, Glowinski J, Prémont J (1985b): Modulation by monoamines of somatostatin-sensitive adenylate cyclase on neuronal and glial cells in primary cultures. J Neurochem 44:1825-1831.
10. Civelli O, Bunzow JR, Grandy DK (1993): Molecular diversity of the dopamine receptors. Annu Rev Toxicol 32:281-307.
11. Colás B, Prieto JC, Arilla E (1990): Somatostatin binding to dissociated cells from rat cerebral cortex. Peptides 11:1109-1112.
12. Colás B, Cambillau C, Buscail L, Zeggari M, Estève JP, Lautre V, Thomas F, Vaysse N, Susini C (1992a): Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells. Eur J Biochem 207:1017-1024.
13. Colás B, Arilla E, Prieto JC (1992b): Somatostatin binding to a fresh rat astrocyte-enriched suspension. Neuropeptides 23:1-7.
14. Constantinidis J, De la Torre JC, Tissot R, Geissbuhler F (1969): The capillary barrier for Dopa in brain and different organs. Psychopharmacology 15:75-87.
15. de los Frailes MT, Cacicedo L, Lorenzo MJ, Tolón RM, Fernández G, Sánchez-Franco F (1993): Neurotransmitter regulation of somatostatin secretion by fetal rat cerebral cortical cells in culture. J Endocrinol Invest 16:661-668.
16. Dorflinger LJ, Schonbrunn A (1983): Somatostatin inhibits basal and vasoactive intestinal peptide-stimulated hormone release by different mechanisms in GH pituitary cells. Endocrinology 113:1551-1558.
17. Epelbaum J (1986): Somatostatin in the central nervous system: physiology and pathological modifications. Prog Neurobiol 27:63-100.
18. Epelbaum J, Javoy-Agid E, Enjalbert A, Krantic S, Kordon C, Agid Y (1988): Somatostatin concentrations and binding sites in human frontal cortex are differentially affected in Parkinson's disease associated dementia and in progressive supranuclear palsy. J Neurol Sci 87:167-174.
19. García-Sevilla JA, Magnusson T, Carlsson A (1978): Effect of intracerebroventricularly administered somatostatin on brain monoamine turnover. Brain Res 155:159-164.
20. Garlind A, Fowler CJ, Alafuzoff I, Winblad B, Cowburn RF (1992): Neurotransmitter-mediated inhibition of post-mortem human brain adenylyl cyclase. J Neural Transm 87:113-124.
21. Giambalvo CT, Wagner RL (1994): Activation of D1 and D2 dopamine receptors inhibits protein kinase C activity in striatal synaptosomes. J. Neurochem 63:169-176.
22. Gilman AG (1970): A protein binding assay for adenosine 3′5′-cyclic monophosphate. Proc Natl Acad Sci USA 67:305-312.
23. 3H]DOPA in various regions of the brain. J Neurochem 13:655-669.
24. 131I-labeled human growth hormone of high specific radioactivity. Biochem J 89:114-123.
25. Haroutunian V, Martin R, Campbell G, Tsuboyama G, Davis K (1987): Cysteamine-induced depletion of central somatostatin-like immunoreactivity: effects on behavior, learning, memory and brain neurochemistry. Brain Res 403:234-242.
26. Houslay MD, Metcalfe JC, Warren GB, Hesketh TR, Smith GA (1976): The glucagon receptor of rat liver plasma membranes can couple to adenylate cyclase without activating it. Biochim Biophys Acta 436:489-494.
27. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PPA, O'Carrol AM, Patel YC, Schonbrunn A, Taylor JE, Reisine T (1995) Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 16:86-88.
28. Joels M, Madamba SG, Moore SD, Morrison JH, Siggins GR (1990): Somatostatin immunohistochemistry of hippocampal slices with Lucifer yellow-stained pyramidal neurons responding to somatostatin. Regul Pept 28:215-221.
29. 2-receptor-mediated, dopamine-induced release of somatostatin. Endocrinology 126:1534-1540.
30. Laburthe M, Breant B, Rouyer-Fessard C (1984): Molecular identification of receptors for vasoactive intestinal peptide in rat intestinal epithelium by covalent cross-linking. Evidence for two classes of binding sites with different structural and functional properties. Eur J Biochem 139:181-187.
31. Laemmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951): Protein measurement with Folin phenol reagent. J Biol Chem 193:265-275.
33. Martin-Iverson MT, Radke JM, Vincent SR (1986): The effects of cysteamine on dopamine-mediated behaviours: evidence for dopamine-somatostatin interactions in the striatum. Pharmacol Biochem Behav 24:1707-1714.
34. Matozaki T, Sakamoto C, Nagao M, Baba S (1986): Phorbol ester or diacylglycerol modulates somatostatin binding to its receptors on rat pancreatic acinar cell membranes. J Biol Chem 261:1414-1420.
35. 2a receptors. Psychopharmacology 117: 193-199.
36. Moser A, Reavill C, Jenner P, Marsden CD, Cramer H (1986): Effects of somatostatin on dopamine sensitive adenylate cyclase activity in the caudate-putamen of the rat. Exp Brain Res 62:567-571.
37. Müller EE, Pra PD, Pecile A (1968): Influence of brain neurohumors injected into the lateral ventricle of the rat on growth hormone release. Endocrinology 83:893-896.
38. Mumby SM, Kahn RA, Manning DR, Gilman AG (1986): Antisera of designed specificity for subunits of guanine nucleotide-binding regulatory proteins. Proc Natl Acad Sci USA 83:265-269.
39. Munson PJ, Rodbard D (1980): LIGAND: a versatile computerized approach for characterization of ligand binding systems. Anal Biochem 107:220-239.
40. Murray-Whelan R, Schlegel W (1992): Brain somatostatin receptor-G protein interaction. J Biol Chem 267:2960-2965.
41. Noble EP, Wurtman RJ, Axelrod J (1967): A simple and rapid method for injecting H3-norepinephrine into the lateral ventricle of the rat brain. Life Sci 6:281-291.
42. Patel JC, Reichlin S (1978): Somatostatin in hypothalamus, extrahypothalamic brain and peripheral tissues of the rat. Endocrinology 102:523-531.
43. Reisine T (1990): Pertussis toxin in the analysis of receptor mechanisms. Biochem Pharmacol 39:1499-1504.
44. Reubi JC (1984): Evidence for two somatostatin-14 receptor subtypes in rat brain cortex. Neurosci Lett 49:259-263.
45. Richardson SB, Nguyen T, Hollander CS (1983): Dopamine stimulates somatostatin release from perfused hypothalamic cells. Am J Physiol 244:E560-E567.
46. Robbins R (1985): Somatostatin and the cerebral cortex. In Patel YC, Tannenbaum GS (eds): "Somatostatin." New York: Plenum Press, pp 201-215.
47. Rubinow DR, Davis CL, Post RM (1992): Somatostatin in neuropsychiatric disorders. In Weil C, Müller EE, Thorner MO (eds): "Basic and Clinical Aspects of Neuroscience." vol 4. Heidelberg: Springer-Verlag, pp 29-42.
48. Salin P, Mercugliano M, Chesselet MF (1990): Differential effects of chronic treatment with haloperidol and clozapine on the level of preprosomatostatin mRNA in the striatum, nucleus accumbens and frontal cortex of the rat. Cell Mol Neurobiol 10:127-144.
49. Scatchard G (1949): The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51:660-671.
50. Schettini G, Florio T, Meucci O, Landolfi E, Grimaldi M, Ventra C, Marino A (1989): Somatostatin inhibition of adenylate cyclase activity in different brain areas. Brain Res 492:65-71.
51. Schonbrunn A, Rorstad OP, Westendorf JF, Martin JB (1983): Somatostatin analogs: correlation between receptor affinity and biological potency in GH pituitary cells. Endocrinology 113:1559-1567.
52. Seamon KB, Daly JW (1986): Forskolin: its biological and chemical properties. In Seamon KB, Daly JW (eds): "Advances in Cyclic Nucleotide and Protein Phosphorylation Research." vol 17. New York: Raven Press, pp 1-50.
53. See RE, Striplin C, Kalivas PW (1993): Chronic haloperidol does not alter G protein α-subunit levels in rats. Mol Brain Res 19:219-221.
54. 3H]dopamine following intracerebroventricular injection in rats pretreated with ethanol or chloral hydrate. Neuropharmacology 22:279-286.
55. Srikant CB, Patel YC (1981): Somatostatin receptors: identification and characterization in rat brain membranes. Proc Natl Acad Sci USA 78:3930-3934.
56. Takagi H, Somogyi P, Somogyi J, Smith AD (1993): Fine structural studies on type of somatostatin-immunoreactive neuron and its synaptic connections in the rat neostriatum: a correlated light and electron microscopic study. J Comp Neurol 214:1-16.
57. Tatsuoka Y, Riskind PN, Beal MF, Martin JB (1987): The effect of amphetamine on the in vivo release of dopamine, somatostatin and neuropeptide Y from rat caudate nucleus. Brain Res 411:200-203.
58. Vécsei L, Bollók I, Telegdy G (1983): The effect of linear somatostatin on the active avoidance behaviour and open-field activity on haloperidol, phenoxybenzamine and atropine pretreated rats. Acta Physiol Hung 62:205-211.
59. Wang HL, Bogen C, Reisine T, Dichter M (1989): Somatostatin-14 and somatostatin-28 induce opposite effects on potassium currents in rat neocortical neurons. Proc Natl Acad Sci USA 86:9616-9620.
60. Wang HL, Reisine T, Dichter M (1990): Somatosiatin-14 and somatostatin-28 inhibit calcium currents in rat neocortical neurons. Neuroscience 38:335-342.
61. Weiss LT, Chesselet MF (1989): Regional distribution and regulation of preprosomatostatin messenger RNA in the striatum, as revealed by in situ hybridization histochemistry. Mol Brain Res 1:121-130.
62. Yu S, Ho IK (1990): Effects of GABA antagonists, SR 95531 and bicuculline on GABA A receptor-regulated chloride flux in rat cortical synaptosomes. Neurochem Res 15:905-910.